These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 19362676)

  • 1. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies.
    Ferguson MW; Duncan J; Bond J; Bush J; Durani P; So K; Taylor L; Chantrey J; Mason T; James G; Laverty H; Occleston NL; Sattar A; Ludlow A; O'Kane S
    Lancet; 2009 Apr; 373(9671):1264-74. PubMed ID: 19362676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scar-improving efficacy of avotermin administered into the wound margins of skin incisions as evaluated by a randomized, double-blind, placebo-controlled, phase II clinical trial.
    Bush J; Duncan JAL; Bond JS; Durani P; So K; Mason T; O'Kane S; Ferguson MWJ
    Plast Reconstr Surg; 2010 Nov; 126(5):1604-1615. PubMed ID: 21042116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial.
    So K; McGrouther DA; Bush JA; Durani P; Taylor L; Skotny G; Mason T; Metcalfe A; O'Kane S; Ferguson MWJ
    Plast Reconstr Surg; 2011 Jul; 128(1):163-172. PubMed ID: 21701333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avotermin: a novel antiscarring agent.
    Durani P; Occleston N; O'Kane S; Ferguson MW
    Int J Low Extrem Wounds; 2008 Sep; 7(3):160-8. PubMed ID: 18757391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avotermin for the improvement of scar appearance: a new pharmaceutical in a new therapeutic area.
    Occleston NL; Fairlamb D; Hutchison J; O'Kane S; Ferguson MW
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1231-9. PubMed ID: 19604123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II clinical trial of avotermin versus placebo for scar improvement.
    McCollum PT; Bush JA; James G; Mason T; O'Kane S; McCollum C; Krievins D; Shiralkar S; Ferguson MW
    Br J Surg; 2011 Jul; 98(7):925-34. PubMed ID: 21618480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of avotermin (transforming growth factor β3) in a clinically relevant pig model of long, full-thickness incisional wounds.
    Laverty HG; Occleston NL; Johnson M; Little J; Jones R; Fairlamb D; Ferguson MW; O'Kane S
    J Cutan Med Surg; 2010; 14(5):223-32. PubMed ID: 20868619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention.
    Ferguson MW; O'Kane S
    Philos Trans R Soc Lond B Biol Sci; 2004 May; 359(1445):839-50. PubMed ID: 15293811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring.
    Occleston NL; O'Kane S; Laverty HG; Cooper M; Fairlamb D; Mason T; Bush JA; Ferguson MW
    Wound Repair Regen; 2011 Sep; 19 Suppl 1():s38-48. PubMed ID: 21793965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-10 reduces scar formation in both animal and human cutaneous wounds: results of two preclinical and phase II randomized control studies.
    Kieran I; Knock A; Bush J; So K; Metcalfe A; Hobson R; Mason T; O'Kane S; Ferguson M
    Wound Repair Regen; 2013; 21(3):428-36. PubMed ID: 23627460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study.
    Ziade M; Domergue S; Batifol D; Jreige R; Sebbane M; Goudot P; Yachouh J
    J Plast Reconstr Aesthet Surg; 2013 Feb; 66(2):209-14. PubMed ID: 23102873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor β3 for the prevention of vocal fold scarring.
    Ohno S; Hirano S; Kanemaru S; Kitani Y; Kojima T; Ishikawa S; Mizuta M; Tateya I; Nakamura T; Ito J
    Laryngoscope; 2012 Mar; 122(3):583-9. PubMed ID: 22252900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and reduction of scarring in the skin by Transforming Growth Factor beta 3 (TGFbeta3): from laboratory discovery to clinical pharmaceutical.
    Occleston NL; Laverty HG; O'Kane S; Ferguson MW
    J Biomater Sci Polym Ed; 2008; 19(8):1047-63. PubMed ID: 18644230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of interleukin-10 on cutaneous wounds and scars in humans of African continental ancestral origin.
    Kieran I; Taylor C; Bush J; Rance M; So K; Boanas A; Metcalfe A; Hobson R; Goldspink N; Hutchison J; Ferguson M
    Wound Repair Regen; 2014; 22(3):326-33. PubMed ID: 24844332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Dermal Thickness on Scars in Women with Type III-IV Fitzpatrick Skin.
    Ince B; Dadaci M; Oltulu P; Altuntas Z; Bilgen F
    Aesthetic Plast Surg; 2015 Jun; 39(3):318-24. PubMed ID: 25787787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early intervention with non-ablative fractional laser to improve cutaneous scarring-A randomized controlled trial on the impact of intervention time and fluence levels.
    Karmisholt KE; Wenande E; Thaysen-Petersen D; Philipsen PA; Paasch U; Haedersdal M
    Lasers Surg Med; 2018 Jan; 50(1):28-36. PubMed ID: 28815643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scar redness in humans: how long does it persist after incisional and excisional wounding?
    Bond JS; Duncan JAL; Mason T; Sattar A; Boanas A; O'Kane S; Ferguson MWJ
    Plast Reconstr Surg; 2008 Feb; 121(2):487-496. PubMed ID: 18300967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
    Kirsner RS; Marston WA; Snyder RJ; Lee TD; Cargill DI; Slade HB
    Lancet; 2012 Sep; 380(9846):977-85. PubMed ID: 22863328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new approach for the prophylactic improvement of surgical scarring: avotermin (TGF beta 3).
    Young VL; Bush J; O'Kane S
    Clin Plast Surg; 2009 Apr; 36(2):307-13, viii. PubMed ID: 19309655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.